The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase III study of gemcitabine and cisplatin (GC) versus dose dense methotrexate, vinblastine, doxorubicin and cisplatin (DD-MVAC) in the perioperative setting for patients with locally advanced transitional cell cancer of the bladder: The French GETUG/AFU V05 VESPER trial.
 
Christian Pfister
No Relationships to Disclose
 
Gwenaelle Gravis
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Janssen Oncology; NOVARTIS; SANOFI; Takeda
 
Geraldine Pignot
No Relationships to Disclose
 
Aude Flechon
No Relationships to Disclose
 
Michel Soulie
No Relationships to Disclose
 
Christine Chevreau
No Relationships to Disclose
 
Laurent Guy
No Relationships to Disclose
 
Brigitte Laguerre
No Relationships to Disclose
 
Nicolas Mottet
No Relationships to Disclose
 
Florence Joly
Consulting or Advisory Role - AstraZeneca; BMS Brazil; Janssen; Novartis; Roche; Sanofi; Tesaro
Research Funding - Astellas Pharma; Janssen
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Roche; tesaro
 
Michel Henry-Amar
No Relationships to Disclose
 
Francois Radvanyi
No Relationships to Disclose
 
Yves Allory
No Relationships to Disclose
 
Stephane Culine
No Relationships to Disclose